JPMorgan lowered the firm’s price target on Molecular Partners to $4.50 from $6.60 and keeps a Neutral rating on the shares. In 2024, the analyst expects the European pharma and biotech sector to continue to outperform the wider market, but only because the firm expects the quality names to carry the sector as happened in 2023. JPMorgan does not expect 2024 to be a year when the “have-nots” stage a comeback, as it continues to see a bifurcation in pharma company outlooks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MOLN:
- Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
- Molecular Partners present updated data from Phase 1 trial of MP0317
- Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
- Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
- Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
